For biopharma CEOs, CFOs, Chief Digital Officers, and Chief Operating Officers evaluating why their AI investments are not yet generating enterprise-scale returns and what it will take to change that.
Biopharma is not short on AI ambition. What’s scarce is time-to-value.
The industry is increasingly governed by three hard constraints: time (the patent clock), productivity (many failures before success), and economics (the cost required to produce a successful outcome). Add in loss of exclusivity, higher evidence expectations, persistent cycle-time bottlenecks, and tighter capital, and the C-Suite mandate becomes unavoidable: compress timelines, increase throughput, and reduce cost per outcome.
AI should be a powerful lever against these constraints. It can automate and accelerate work, improve decision quality, reduce rework, and increase the marginal productivity of scarce, expert talent. Yet the enterprise value isn’t showing up at scale: global surveys indicate more than two-thirds of organizations have not yet begun scaling AI across the enterprise.
This is not a technology problem. It is a leadership and operating problem. Across biopharma, three recurring “breaking points” consistently stall outcomes, directly undermining speed, productivity, and economics. These points are illustrated in Figure 1 and the supporting detailed points below:
Figure 1: The Biopharma AI Breaking Points Model
Most AI programs start with enthusiasm (“AI-first,” “GenAI copilots,” “automation at scale”), but face challenges in translating that ambition into an explicit set of workflow priorities tied to the constraints faced in the biopharma industry. Accountability for value is often unclear, benefits tracking is inconsistent, and the predictable result is a large volume of pilots with slow scale-up and limited compounding ROI.
In practice, this may look like the following:
When strategy isn’t converting into full, tangible value creation, AI is seen as an activity rather than a growth driver to improve P&Ls.
In the push for speed, organizations often lock into vendor platforms or point solutions too early, creating integration debt, limiting flexibility, or failing to meet evolving expectations for regulated workflows. Leaders find themselves caught between conflicting objectives: move fast, but also protect security, compliance, auditability, and optionality as the landscape evolves.
The trap is that platform risk rarely shows up in a pilot, but presents itself at scale, resulting in:
Moving fast becomes a fragile, high-risk experience, and the organization is unable to create production-grade AI solutions at the speed required to be competitive.
Even with a clear strategy and the appropriate solutions, AI does not scale without biopharma-fluent talent and adoption mechanics.
Across organizations, there is typically a scarce presence of biopharma-domain AI expertise and insufficient workflow integration support, leading to stalled adoption. Many programs measure success as deployed AI rather than sustained utilization, performance, and behavioral change. The consequences are low utilization, shadow processes, and minimal impact on the constraints that matter at the enterprise level.
This is the most expensive failure mode because it destroys opportunity for compounded value. Specific outcomes may include the following:
If adoption is not engineered into workflows, incentives, and performance management, AI will remain a series of pilots, no matter how impressive the model is.
The recurring breakpoints above are not rooted in AI capability. They are rooted in portfolio, operations, and adoption mechanics. A portfolio approach works because it treats AI like a managed enterprise system, linking strategy to a funded pipeline, delivery to repeatable execution, and deployment to sustainable adoption using governance and metrics that are relevant to the C-Suite. The result is a flywheel effect: each successful deployment improves the economics of the next, shortening time to production, lowering marginal delivery cost, and increasing the probability of sustained value. This portfolio response is illustrated in Figure 2 below:
Figure 2: The Portfolio Response | Three Shifts to Scale AI
To escape the AI biopharma breaking points and build a successful AI portfolio that compounds value at scale, executives must honestly evaluate their operational readiness. Before authorizing another pilot, ask your team:
By answering these questions, organizations can begin shifting from isolated use cases to a governed AI pipeline, setting the stage for the AI value operating flywheel. In part 2 of the series, we will discuss the AI Value Operating Flywheel in detail and how to design the optimal portfolio for a biopharma organization.
Greg Caldwell brings a combination of commercial acuity, enterprise strategy, and operational leadership built across more than a decade of experience advising biopharma executive teams at inflection points where the quality of decisions directly determines enterprise growth, asset value, and time to patient. At Scimitar, he serves as Principal and spearheads the firm’s AI and Digital work, partnering with teams to translate ambition into measurable enterprise value; he is also a member of the Commercial Leadership team. Greg has deep experience across commercial and corporate strategy, including portfolio and pipeline strategy, new product planning, M&A, launch, and operating model design and transformation across oncology, rare disease, neurology, and cardiology. His prior experiences shape the analytical rigor and pragmatic execution he leverages to help organizations navigate their most critical inflection points to realize tangible value.
greg.caldwell@scimitar.com
| Intended Reader For biopharma CEOs, CFOs, Chief Digital Officers, and Chief Operating Officers evaluating why their AI investments are not yet generating enterprise-scale returns
| Intended Reader For biopharma leaders looking to transform their organizations at scale by adopting digital and GenAI solutions. | Key Takeaways Don’t know when
Strategic Growth, Patient Benefits, and Practical Challenges | Intended Reader For biopharma leaders, clinical operations teams, and research organizations seeking data-driven insights into the current
Modality Diversity, Target Selection, and Portfolio Strategy Creating a Perfect Storm of Complexity
Modality Diversity, Target Selection, and Portfolio Strategy Creating a Perfect Storm of Complexity
Modality Diversity, Target Selection, and Portfolio Strategy Creating a Perfect Storm of Complexity